ST. LOUIS, July 31, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tuesday, August 7, 2018 before the open of […]
Tag: Stereotaxis
Stereotaxis and Johnson & Johnson’s Biosense Webster Extend Development Alliance and Supply Agreement
ST. LOUIS, June 25, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with Johnson & Johnson’s Biosense Webster, Inc. The amendment […]
Stereotaxis Announces Changes to its Board of Directors
ST. LOUIS, June 04, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of directors. Mr. Levin is the Director of Research at Arbiter Partners, a successful New […]
Stereotaxis to Present at 8th Annual LD Micro Invitational
ST. LOUIS, May 22, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 8th Annual LD Micro Invitational. Mr. Fischel will provide an […]
Stereotaxis’ Leadership in Robotic Cardiac Ablation to be Showcased at Heart Rhythm 2017 and First Annual Meeting of Society for Cardiac Robotic Navigation (Americas)
ST. LOUIS, April 25, 2017 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at McCormick Place in Chicago from May 10-13. With a message […]
Clinical study validates efficiencies of Stereotaxis Niobe ES system compared to Niobe II system
ST. LOUIS, March 14, 2017 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported results of a study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France, which validates the advantages of the Niobe ® ES magnetic navigation […]
Recent
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
Simpson Interventions Announces First Patients Treated in Clinical Trial for its Acolyte™ Catheter System
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
Popular
- No commented posts yet